Blood Reviews
Volume 20, Issue 1 , Pages 15-27 , January 2006

Chronic graft-versus-host disease

References 

  1. Grebe SC, Streilein JW. Graft-versus-host reactions: a review. Adv Immunol. 1976;22:119–221
  2. Hathaway WE, Githens JH, Blackburn WR, et al. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. N Engl J Med. 1965;273:953–958
  3. Beschorner WE, Tutschka PJ, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. I. Clinical features, hematology, histology, and immunopathology in long-term chimeras. Transplantation. 1982;33:393–399
  4. Tutschka P, Teasdall R, Beschorner WE, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. II. Immunological evaluation in long-term chimera. Transplantation. 1982;34:289–294
  5. Atkinson K, Incefy GS, Storb R, et al. Low serum thymic hormone levels in patients with chronic graft-versus-host disease. Blood. 1982;59:1073–1077
  6. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458–1466
  7. Reinherz EL, Parkman R, Rappeport J, Rosen FS, Schlossman SF, et al. Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med. 1979;300:1061–1068
  8. Fialkow P, Gilchrist C, Allison AC. Autoimmunity in chronic graft-versus-host disease. Clin Exp Immunol. 1973;13:479–486
  9. Graze PR, Gale RP. Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med. 1979;66:611–620
  10. Lister J, Messner H, Keysteon E, et al. Autoantibody analysis of patients with graft-versus-host disease. J Clin Lab Immunol. 1987;24:19–23
  11. Rouquette-Gally AM, Boyeldieu D, Prost AC, et al. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation. 1988;46:238–240
  12. Dighiero G, Intrator L, Cordonnier C, et al. High levels of anti-cytoskeleton autoantibodies are frequently associated with chronic GVHD. Br J Haematol. 1987;67:301–305
  13. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transpl. 1990;6:93–96
  14. Wesierska-Gadek J, Penner E, Hitchman E, et al. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood. 1992;79:1081–1086
  15. Bell SA, Faust H, Mittermuller J, et al. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol. 1996;134:848–854
  16. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259
  17. Remberger M, Aschan J, Lonnqvist B, et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol. 2001;66:50–56
  18. Wagner JL, Seidel K, Boeckh M, et al. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival. Biol Blood Marrow Transpl. 2000;6:633–639
  19. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2002;8:674–682
  20. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood. 1995;86:1228–1234
  21. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051
  22. Ho VT, Mirza NQ, del Junco D, Okamura T, Przepiorka D, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transpl. 2003;32:771–775
  23. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the acute leukemia working party of the European group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:Number 3
  24. Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood. 2000;96:2703–2711
  25. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–3227
  26. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996;88:2794–2800
  27. Schmitz N, Bacigalupo A, Labopin M. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. Brit J Haem. 1996;95:715–723
  28. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705–4709
  29. Majolino I, Saglio G, Scime R, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transpl. 1996;17:555–560
  30. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95:3702–3709
  31. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695–1700
  32. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood. 2001;98:2900–2908
  33. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 2002;100:3128–3134
  34. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–3691
  35. Nagler A, Goldenhersh MA, Levi-Schaffer F, et al. Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. Br J Dermatol. 1996;134:780–783
  36. Ueda M, Mori T, Shiobara S, et al. Development of bullous pemphigoid after allogeneic bone marrow transplantation. Report of a case. Transplantation. 1986;42:320–322
  37. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276
  38. Yau JC, Zander AR, Srigley JR, et al. Chronic graft-versus-host disease complicated by micronodular cirrhosis and esophageal varices. Transplantation. 1986;41:129–130
  39. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet. 1980;1:1166–1168
  40. Benyunes MC, Sullivan K, Deeg HJ. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995;32:661–670
  41. Schubert MM, Sullivan KM, Morton TH, et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med. 1984;144:1591–1595
  42. Schwarer AP, Hughes JM, Trotman-Dickenson B, et al. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation. 1992;54:1002–1008
  43. Duncker C, Dohr D, Harsdorf S, et al. Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome. Bone Marrow Transpl. 2000;25:1263–1268
  44. Clark JG, Schwartz DA, Flournoy N, et al. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med. 1987;107:648–656
  45. Sullivan KM, Shulman HM. Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. Transpl Proc. 1989;21:51–62
  46. Holland HK, Wingard JR, Beschorner WE, et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood. 1988;72:621–627
  47. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transpl. 2003;9:657–666
  48. McDonald GB, Sullivan KM, Schuffler MD, et al. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology. 1981;80:914–921
  49. McDonald G, Sullivan KM, Plumley TF. Radiographic features of esophageal involvement in chronic graft-versus-host disease. Am J Roentgenol. 1984;142:501–506
  50. Corson SL, Sullivan K, Batzer F, et al. Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol. 1982;60:488–492
  51. Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transpl. 1990;5:425–430
  52. Seber A, Khan SP, Kersey JH. Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Bone Marrow Transpl. 1996;17:207–211
  53. Peralvo J, Bacigalupo A, Pittaluga PA, et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transpl. 1987;2:279–285
  54. Gomez-Garcia P, Herrera-Arroyo C, Torres-Gomez A, et al. Renal involvement in chronic graft-versus-host disease: a report of two cases. Bone Marrow Transpl. 1988;3:357–362
  55. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579–585
  56. Atkinson K, Norrie S, Chan P, et al. Hemopoietic progenitor cell function after HLA-identical sibling bone marrow transplantation: influence of chronic graft-versus-host disease. Int J Cell Cloning. 1986;4:203–220
  57. Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood. 1989;73:1054–1058
  58. Godder K, Pati AR, Abhyankar SH, et al. De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant. Bone Marrow Transpl. 1997;19:813–817
  59. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133:275–279
  60. Siadak MF, Kopecky K, Sullivan KM. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Clin Exp Immunol. 1994;97(Suppl 1):53–57
  61. Seidler C, Mills L, Flowers M, et al. Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. Amer J Hematol. 1994;45:240–243
  62. Socie G, Selimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol. 1994;86:624–628
  63. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transpl. 2001;7:257–264
  64. Sanders J. Effects of chronic graft-versus-host disease on growth and development. In:  Burakoff SJ,  Deeg HJ,  Ferrara J,  Atkinson K editor. Graft-versus-host disease: immunology, pathphysiology, and treatment. vol. 37:New York: Marcel Dekker, Inc.; 1990;p. 665–680
  65. Loughran T, Sullivan K. Early detection and monitoring of chronic graft-versus-host disease. [chapter 35] In:  Burakoff SJ,  Deeg HJ,  Ferrara J,  Atkinson K editor. Graft-versus-host disease: immunology, pathphysiology, and treatment. New York: Marcel Dekker; 1990;p. 631–636
  66. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  67. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transpl. 1989;4:247–254
  68. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97:1219–1226
  69. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003;102:802–809
  70. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–414
  71. Loughran TP, Sullivan K, Morton T, et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76:228–234
  72. Wagner JL, Flowers ME, Longton G, et al. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transpl. 1998;22:139–146
  73. Jacobsohn DA, Montross S, Anders V, et al. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transpl. 2001;28:1047–1051
  74. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia.. Blood. 1991;78:2120–2130
  75. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485–494
  76. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–712
  77. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transpl. 1996;2:44–53
  78. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942–2947
  79. Chakrabarti S, MacDonald D, Hale G, Holder K, Turner V, Czarnecka H, et al. T-cell depletion with Campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol. 2003;121:109–118
  80. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269–275
  81. Santos GW, Tutschka PJ, Brookmeyer R. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophlaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transpl. 1987;1:21–28
  82. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol. 1989;72:567–572
  83. Ruutu T, Volin L, Elonen E. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treament with corticosteroids. Tranpl Proc. 1988;20:491–493
  84. Lonnquist B, Aschan J, Ljungman P, et al. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol. 1990;74:547–548
  85. Bacigalupo A, Maiolino A, Van Lint MT, et al. Cyclosporin A and chronic graft versus host disease. Bone Marrow Transpl. 1990;6:341–344
  86. Storb R, Leisenring W, Anasetti C, et al. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?. Biol Blood Marrow Transpl. 1997;3:194–201
  87. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001;98:3868–3870
  88. Siadak M, Sullivan KM. The management of chronic graft-versus-host disease. Blood Rev. 1994;8:154–160
  89. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51
  90. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055–1058
  91. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699–703
  92. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2001;7:265–273
  93. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995–3996
  94. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA, et al. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transpl. 2003;9:760–765
  95. Hodgson TA, Sahni N, Kaliakatsou F, Buchanan JA, Porter SR, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol. 2003;13:466–470
  96. Kiang E, Tesavibul N, Yee R, Kellaway J, Przepiorka D, et al. The use of topical cyclosporin A in ocular graft-versus-host disease. Bone Marrow Transpl. 1998;22:147–151
  97. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transpl. 1992;10(Suppl 1):127–134
  98. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transpl. 1999;24:517–520
  99. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2000;6:613–620
  100. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transpl. 2000;26:865–869
  101. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604–3609
  102. Lee SJ, Wegner SA, McGarigle CJ, et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997;89:2298–2302
  103. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation. 1990;50:807–811
  104. Deeg HJ, Erickson K, Storb R, et al. Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. Blood Cells. 1992;18:151–161discussion 161-2
  105. Aubin F, Brion A, Deconinck E, et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation. 1995;59:151–155
  106. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transpl. 1996;17:1061–1067
  107. Barr M, Meiser BM, Kur F. Immunomodulation with photopheresis: clinical results of the multi-center cardiac transplantation study: reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation. 1994;57:563–568
  108. Dall’Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6:296–304
  109. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transpl. 1994;14:845–848
  110. Rossetti F, Zulian F, Dall’Amico R, et al. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation. 1995;59:149–151
  111. Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transpl. 1998;4:27–37
  112. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92:3098–3104
  113. Halevy O, Nagler A, Levi-Schaffer F, et al. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol. 1996;52:1057–1063
  114. Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation. 1999;68:1806–1809
  115. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood. 1999;93:66–70
  116. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001;112:820–823
  117. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002;73:665–667
  118. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transpl. 1998;22:61–65
  119. Lopez F, Parker P, Rodriquez D, et al. Efficacy of mycophenolate mofetil (MMF) in the treatment of chronic graft-versus-host disease. Blood. 2001;98(suppl):398a;[abstract]
  120. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2000;6:327–334
  121. Murphy PT, Sivakumaran M, Fahy G, et al. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transpl. 1996;18:641–642
  122. Singhal S, Powles R, Treleaven J, et al. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymph. 1997;24:539–543
  123. Adams F, Messner H. Neuropharamacologic therapy of the neuromuscular manifestations of graft-versus-host disease. Proc Am Soc Clin Oncol. 1987;6:145
  124. Fried R, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 1992;116:624–629
  125. Stern JM, Chesnut CH, Bruemmer B, et al. Bone density loss during treatment of chronic GVHD. Bone Marrow Transpl. 1996;17:395–400
  126. Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. 1998;22:67–71
  127. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:3683–3686
  128. Sullivan KM, Meyers JD, Flournoy N, et al. Early and late interstitial pneumonia following human bone marrow transplantation. Int J Cell Cloning. 1986;4(Suppl 1):107–121
  129. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659–713.
  130. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115:630–641
  131. Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med. 1983;143:1735–1737
  132. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610–615
  133. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  134. Lee S, Cook EF, Soiffer R, et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2002;8:444–452

PII: S0268-960X(05)00008-1

doi: 10.1016/j.blre.2005.01.007

Blood Reviews
Volume 20, Issue 1 , Pages 15-27 , January 2006

Article Tools